Abstract 674P
Background
Insufficient patient enrollment per month (=accrual) is the leading cause of cancer trial termination. This study identifies and quantifies factors associated with patient accrual in trials leading to the US Food and Drug Administration (FDA) approval of new cancer drugs.
Methods
All cancer drugs with FDA approval were identified in the Drugs@FDA database (2000-2022). Data on drug indication’s background-, treatment-, disease-, and trial-related factors were collected from FDA labels, clinicaltrials.gov, and the Global Burden of Disease study. The association between patient accrual and collected variables was assessed in Poisson regression models reporting adjusted rate ratios (aRR) for randomized and single-arm trials.
Results
We identified 170 drugs with approval in 455 cancer indications based on 292 randomized and 163 single-arm trials. Among randomized trials, accrual rates were 0.30-times (p<0.001), 0.73-times (p<0.001), and 0.88-times (p=0.361) lower for ultra-rare, rare, and common than non-orphan indications. Accrual was positively associated with disease burden (aRR: 1.0003 per DALY, p<0.001), trial sites (aRR: 1.001 per site, p<0.001), participating countries (aRR: 1.02 per country, p<0.001), and phase 3 vs. 1/2 trials (aRR: 1.64, p=0.037). Enrollment was negatively associated with advanced-line vs. first-line treatments (aRR: 0.81, p=0.010) and monotherapy vs. combination treatments (aRR: 0.80, p=0.007). Accrual was 0.80-times lower (p=0.209) in government-sponsored vs. industry-sponsored trials. Results were consistent for single-arm trials.
Conclusions
Disease incidence and burden alongside the number of study sites and participating countries were significantly associated with patient accrual. For rare disease trials, greater financial incentives could expedite patient enrollment. Novel trial design features, including skewed randomization, crossover, or open-label masking, did not entice patient enrollment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
723P - A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy
Presenter: Li Xiaoling Li
Session: Poster session 01
724P - Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
Presenter: Guiling Li
Session: Poster session 01
725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
Presenter: Dominik Denschlag
Session: Poster session 01
726P - Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025
Presenter: Kosei Hasegawa
Session: Poster session 01
727P - Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China
Presenter: Yang Sun
Session: Poster session 01
Resources:
Abstract
728P - Chemotherapy plus tislelizumab in young patients with cervical cancer preserve fertility: A phase II study
Presenter: Danbo Wang
Session: Poster session 01
729P - Patterns of survivorship care of cervical cancer patients with or without HIV infection in Botswana 2015-2022
Presenter: Sheldon Amoo-Mitchual
Session: Poster session 01
730P - Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
Presenter: Guillaume Beinse
Session: Poster session 01
731P - Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
Presenter: Mansoor Raza Mirza
Session: Poster session 01
732P - Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Presenter: Stephanie Blank
Session: Poster session 01